CureMeAbroad
Ferhat Ferhatoglu

Ferhat Ferhatoglu

Cancer Treatment

12+

Years of Experience

About Ferhat Ferhatoglu

<p>Education and Specialization</p><p> 2017 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine</p><p> 19 November 2020 Istanbul University Istanbul Faculty of Medicine, Department of Medical Oncology</p><p> 2011-25 June 2015 Hospitals / Istanbul Haydarpasa Numune Education and Research Hospital</p><p> 2004 Mersin University Faculty of Medicine</p><p></p><p> Experience</p><p> 13.11.2017-29.03.2021 Istanbul University Istanbul Faculty of Medicine Internal Medicine Departments, Department of Internal Medicine</p><p> 21.03.2011-25.06.2015 Istanbul Haydarpasa Numune Education and Research Hospital<br /><br /><br /><br /> Ferhatoğlu Ferhat, Çağatay Tulin, Okumuş Nigar Gülfer, Aydıner Adnan, Paksoy Nail, Ak Naziye, Aydın Esra, Saip Pinar Mualla (2023). Laterality Of Adrenal Gland Metastasis In Lung Cancer: Results Of A Comparative Study. Eurasian Journal Of Medical Investigatin, 7(2), 101-106., Doi: 10.14744/Ejmi.2023.58954</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942</p><p style="margin-left:26.7pt;"> TAŞTEKİN DİDEM, PAKSOY NAİL, DOĞAN İZZET, FERHATOĞLU FERHAT, KHANMAMMADOV NIJAT, BOZBEY HAMZA UGUR, KARABULUT SENEM (2023). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first?line treatment of metastatic gastric cancer: A single?center experience. Journal of Cancer Research and Therapeutics, 19(2), 253-258., Doi: 10.4103/jcrt.jcrt_672_22 (Quarterly=Q4)</p><p style="margin-left:26.7pt;"> KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340</p><p style="margin-left:26.7pt;"> KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, AYDINER ADNAN, PAKSOY NAİL (2022). Evaluation of clinical features and risk factors related to late recurrence (&gt;5 years) in patients with breast cancer. Journal of Surgery and Medicine, 6(12), 986-990., doi: 10.28982/josam.7610</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, ERTÜRK KAYHAN, TAŞ FARUK (2022). Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences. Journal of Cancer Research and Therapeutics, 0, Doi: 10.4103/jcrt.jcrt_815_21</p><p style="margin-left:26.7pt;"> ÖZGÜR EMRE, FERHATOĞLU FERHAT, ŞEN FATMA, GEZER UĞUR (2022). Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast Cancer. BALKAN MEDICAL JOURNAL, 39(6), 450-451., Doi: 10.4274/balkanmedj.galenos.2022.2022-5-18</p><p style="margin-left:26.7pt;"> <strong>Articles</strong></p><p style="margin-left:26.7pt;"> TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates. JOURNAL OF COSMETIC DERMATOLOGY, 21(4), 1570-1573., Doi: 10.1111/jocd.14278</p><p style="margin-left:26.7pt;"> TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis. Indian Journal of Surgery, Doi: 10.1007/s12262-022-03532-y</p><p style="margin-left:26.7pt;"> DOĞAN İZZET, GÜRBÜZ MUSTAFA, PAKSOY NAİL, FERHATOĞLU FERHAT, VATANSEVER SEZAİ, SAİP PINAR, DEMİRKAZIK AHMET, AYDINER ADNAN (2022). Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine, 101(34), 30188, Doi: 10.1097/MD.0000000000030188</p><p style="margin-left:26.7pt;"> PAKSOY NAİL, KHANMAMMADOV NIJAT, DOĞAN İZZET, FERHATOĞLU FERHAT, YILDIZ ANIL, AK NAZİYE, AYDINER ADNAN (2022). Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study. Medicine, 101(45), 31726, Doi: 10.1097/MD.0000000000031726</p><p style="margin-left:26.7pt;"> PAKSOY NAİL, FERHATOĞLU FERHAT, DOĞAN İZZET, KHANMAMMADOV NIJAT, İRİBAŞ ÇELİK AYÇA, GÜLBAŞ ZAFER, BAŞARAN MERT (2022). High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience. Medicine, 101(49), 32213, Doi: 10.1097/MD.0000000000032213</p><p style="margin-left:26.7pt;"> ÇİL İBRAHİM, KÜÇÜKARDA AHMET, ATCI MUHAMMED MUSTAFA, SECMELER SABAN, PAKSOY NAİL, FERHATOĞLU FERHAT, AK NAZİYE, AYHAN MURAT, TATAROĞLU ÖZYÜKSELER DENİZ, ÖNDER ARİF HAKAN, AVCI OKAN, OYMAN ABDİLKERİM, OKTEN ILKER NIHAT, GÜLTÜRK İLKAY, AKAGÜNDÜZ BARAN, BASOĞLU TÜYLÜ TUĞBA, ÇAKIR EMRE, HACIBEKİROĞLU İLHAN, ÖZÇELİK MELİKE, AYDINER ADNAN (2022). Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori Journal, 108(1), 19-25., Doi: 10.1177/03008916211037739</p><p style="margin-left:26.7pt;"> DOĞAN İZZET, KARABULUT SENEM, TAŞTEKİN DİDEM, FERHATOĞLU FERHAT, PAKSOY NAİL, ŞAKAR BURAK (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. Journal of the College of Physicians and Surgeons Pakistan, 32(8), 1014-1019., Doi: 10.29271/jcpsp.2022.08.1014</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, TUĞCU MURAT, APAYDIN SÜHEYLA (2022). Factors Affecting Postoperative Morbidity and Mortality in Chronic Hemodialysis Patients. Eurasian Journal of Medical Advances, 2(3), 30-38., doi: 10.14744/ejma.2022.43153</p><p style="margin-left:26.7pt;"> KAPAĞAN TANJU, FERHATOĞLU FERHAT, RETIRED SELİNAY, KILIÇ ÇAĞLA ECEM (2022). Risk Factors for Cutaneous Melanomas and Level of Awareness in Society. Journal of the Turkish Academy of Dermatology, 16(4), 94-100., Doi: 10.4274/jtad.galenos.2022.30092</p><p style="margin-left:26.7pt;"> FERHATOĞLU FERHAT, ALTAN FERHATOĞLU ZEYNEP (2022). Frequency, Demographic and Clinicopathological Characteristics of Skin Cancer Patients Treated and Followed Up in the Medical Oncology Outpatient Clinic. Journal of the Turkish Academy of Dermatology, 16(4), 77-81., Doi: 10.4274/jtad.galenos.2022.04706</p><p style="margin-left:26.7pt;"> KARABULUT SENEM, DOĞAN İZZET, USUL AFŞAR ÇİĞDEM, KARABULUT MEHMET, KARAMAN ŞULE, FERHATOĞLU FERHAT, TAŞTEKİN DİDEM (2021). Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 27(6), 1357- 1363., Doi: 10.1177/1078155220959427</p><p style="margin-left:26.7pt;"> AK NAZİYE, ÖZKAN BERKER, YENİGÜN BÜLENT MUSTAFA, YILMAZBAYHAN EMİNE DİLEK, TOKER SEYFİ ALPER, FERHATOĞLU FERHAT, YAŞAR HATIME ARZU, DİZBAY SAK SERPİL, TANJU SERHAT, DILEGE MUSTAFA ŞÜKRÜ, ERUS SUAT, BULUTAY PINAR, FIRAT PINAR, MANDEL NİL MOLİNAS, KILIÇKAP SAADETTİN, ONDER SEVGEN, DİKMEN ERKAN, ALAN ÖZKAN, YUMUK PERRAN FULDEN, BOZKURTLAR EMİNE, LAÇİN TUNÇ, YILDIZELİ BEDRETTİN, ÖZTÜRK AKIN, KOCATÜRK CELALETTİN İBRAHİM, KARAPINAR KEMAL, ÜRER HALIDE NUR, OYAN ULUÇ BAŞAK, AYDINER ADNAN, DEMİRKAZIK AHMET, ERALP YEŞİM (2021). The role of adjuvant chemotherapy in resected stage I non-small cell lung cancer: A Turkish Oncology Group Study.. Journal of BUON, 26(3), 819-829.</p><p style="margin-left:26.7pt;"> AK NAZİYE, TOKER SEYFİ ALPER, KARA MURAT, ÖZKAN BERKER, ÜLKER MELİKE GÜLER, KABA ERKAN, YEGEN GÜLÇİN, KARAMAN ŞULE, DAĞOĞLU SAKİN RABİA NERGİZ, KAYTAN SAGLAM ESRA, ORAL ETHEM NEZİH, KİZİR AHMET, BAYRAKTAR SOLEY, DİSTÇİ RIAN, FERHATOĞLU FERHAT, AYDIN ESRA, VATANSEVER SEZAİ, ERALP YEŞİM, AYDINER ADNAN (2021). Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center. TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 29(4), 487- 495., Doi: 10.5606/tgkdc.dergisi.2021.20529</p><p style="margin-left:26.7pt;"> AK NAZİYE, PAKSOY NAİL, FERHATOĞLU FERHAT, AYDIN ESRA, DOĞAN İZZET, BEKTAŞ ERDEM, KARACA MERT, OGUZ SOYDİNÇ HİLAL, MINARECİ YAĞMUR, SÖZEN HAMDULLAH, TOPUZ SAMET, SAİP PINAR MUALLA, VATANSEVER SEZAİ (2021). Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma. TURKISH JOURNAL of ONCOLOGY, 36(4), 438-445., Doi: 10.5505/tjo.2021.2882</p>

Good to know

Speciality

Cancer Treatment

Language Spoken

EnglishTurkish

Clinical oncologist

2017–2021 — Internal Medicine Department at Istanbul University Istanbul Faculty of Medicine

2011–2015 — Istanbul Haydarpasa Numune Education and Research Hospital

All Procedures

Performed by Ferhat Ferhatoglu

Cancer Treatment

Cancer Treatment

Cancer treatment abroad gives patients an access to world-class oncology centers offering chemotherapy, immunotherapy, targeted therapy, radiation, and surgical oncology. Multidisciplinary tumor boards of oncologists, surgeons, and radiologists collaborate to design personalized treatment plans. Oncology care costs can be financially devastating in many countries. Advanced cancer treatments that cost $80,000 to $200,000 at home may be available for $15,000 to $50,000 abroad at JCI-accredited hospitals with equally qualified oncologists and the latest treatment technologies. International cancer centers provide comprehensive care including PET-CT imaging, genomic tumor profiling, and access to clinical trials not available locally. Dedicated oncology case managers guide patients through every step of their treatment journey. The oncologist's experience and the hospital's technology are the most important factors to consider to ensure authenticity. Always confirm your treating team includes board-certified oncologists and that the facility is accredited by a recognized international body. Adherence to your full treatment protocol, nutritional support, and psychological well-being during treatment all significantly influence outcomes.

CureMeAbroadIs Absolutely Free

Just discovery so you can choose what's right for you!

Get a free consultation with CureMeAbroad

World's No. 1 Medical Discovery Platform

Help Me Plan
My Treatment Abroad

End-to-End Treatment Planning, specifically curated to your needs. Just a call away

Plan your treatment abroad with CureMeAbroad